Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series
Identifieur interne : 000149 ( Main/Corpus ); précédent : 000148; suivant : 000150Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series
Auteurs : David A. Gallagher ; Sean S. O'Sullivan ; Andrew H. Evans ; Andrew J. Lees ; Anette SchragSource :
- Movement Disorders [ 0885-3185 ] ; 2007-09-15.
English descriptors
Abstract
Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21611
Links to Exploration step
ISTEX:2FFC1B948CA3345C4CE97037E5E84E73D7651463Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title><author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2FFC1B948CA3345C4CE97037E5E84E73D7651463</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21611</idno><idno type="url">https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000149</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title><author><name sortKey="Gallagher, David A" sort="Gallagher, David A" uniqKey="Gallagher D" first="David A." last="Gallagher">David A. Gallagher</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Evans, Andrew H" sort="Evans, Andrew H" uniqKey="Evans A" first="Andrew H." last="Evans">Andrew H. Evans</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-09-15">2007-09-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1757">1757</biblScope><biblScope unit="page" to="1763">1763</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2FFC1B948CA3345C4CE97037E5E84E73D7651463</idno><idno type="DOI">10.1002/mds.21611</idno><idno type="ArticleID">MDS21611</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine disregulation</term><term>gambling</term><term>impulse control disorder</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>David A. Gallagher MRCP</name><affiliations><json:string>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</json:string><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Sean S. O'Sullivan MRCPI</name><affiliations><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew H. Evans FRACP</name><affiliations><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew J. Lees MD, FRCP</name><affiliations><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Anette Schrag MD, PhD</name><affiliations><json:string>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</json:string><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>gambling</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>impulse control disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine disregulation</value></json:item></subject><articleId><json:string>MDS21611</json:string></articleId><language><json:string>eng</json:string></language><abstract>Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>7.002</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1437</abstractCharCount><pdfWordCount>4326</pdfWordCount><pdfCharCount>27519</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>223</abstractWordCount></qualityIndicators><title>Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>1763</last><first>1757</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21611</json:string></doi><id>2FFC1B948CA3345C4CE97037E5E84E73D7651463</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title><author><persName><forename type="first">David A.</forename><surname>Gallagher</surname></persName><roleName type="degree">MRCP</roleName><affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Sean S.</forename><surname>O'Sullivan</surname></persName><roleName type="degree">MRCPI</roleName><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Andrew H.</forename><surname>Evans</surname></persName><roleName type="degree">FRACP</roleName><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Andrew J.</forename><surname>Lees</surname></persName><roleName type="degree">MD, FRCP</roleName><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Department of Clinical Neurosciences, Royal Free Hospital, University College London, London NW3 2PF, UK</p></note><affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-09-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1757">1757</biblScope><biblScope unit="page" to="1763">1763</biblScope></imprint></monogr><idno type="istex">2FFC1B948CA3345C4CE97037E5E84E73D7651463</idno><idno type="DOI">10.1002/mds.21611</idno><idno type="ArticleID">MDS21611</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>gambling</term></item><item><term>Parkinson's disease</term></item><item><term>impulse control disorder</term></item><item><term>dopamine disregulation</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-03-06">Received</change><change when="2007-05-08">Registration</change><change when="2007-09-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2FFC1B948CA3345C4CE97037E5E84E73D7651463/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v22:12</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2007-09-15">15 September 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21611</doi><idGroup><id type="unit" value="MDS21611"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-03-06"></event><event type="manuscriptRevised" date="2007-04-27"></event><event type="manuscriptAccepted" date="2007-05-08"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-06-19"></event><event type="firstOnline" date="2007-06-19"></event><event type="publishedOnlineFinalForm" date="2007-09-21"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1757</numbering><numbering type="pageLast">1763</numbering></numberingGroup><correspondenceTo>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London NW3 2PF, UK</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21611.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="50"></count><count type="wordTotal" number="4925"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title><title type="short" xml:lang="en">Pathological Gambling in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>David A.</givenNames><familyName>Gallagher</familyName><degrees>MRCP</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Sean S.</givenNames><familyName>O'Sullivan</familyName><degrees>MRCPI</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Andrew H.</givenNames><familyName>Evans</familyName><degrees>FRACP</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Andrew J.</givenNames><familyName>Lees</familyName><degrees>MD, FRCP</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.schrag@medsch.ucl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurology, University College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">gambling</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">impulse control disorder</keyword><keyword xml:id="kwd4">dopamine disregulation</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pathological Gambling in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series</title></titleInfo><name type="personal"><namePart type="given">David A.</namePart><namePart type="family">Gallagher</namePart><namePart type="termsOfAddress">MRCP</namePart><affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sean S.</namePart><namePart type="family">O'Sullivan</namePart><namePart type="termsOfAddress">MRCPI</namePart><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew H.</namePart><namePart type="family">Evans</namePart><namePart type="termsOfAddress">FRACP</namePart><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew J.</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD, FRCP</namePart><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><description>Correspondence: Department of Clinical Neurosciences, Royal Free Hospital, University College London, London NW3 2PF, UK</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-09-15</dateIssued><dateCaptured encoding="w3cdtf">2007-03-06</dateCaptured><dateValid encoding="w3cdtf">2007-05-08</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">50</extent><extent unit="words">4925</extent></physicalDescription><abstract lang="en">Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co‐morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co‐prescribed, suggesting possible cross‐sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti‐parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>gambling</topic><topic>Parkinson's disease</topic><topic>impulse control disorder</topic><topic>dopamine disregulation</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1757</start><end>1763</end><total>7</total></extent></part></relatedItem><identifier type="istex">2FFC1B948CA3345C4CE97037E5E84E73D7651463</identifier><identifier type="DOI">10.1002/mds.21611</identifier><identifier type="ArticleID">MDS21611</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2FFC1B948CA3345C4CE97037E5E84E73D7651463
|texte= Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series
}}
| This area was generated with Dilib version V0.6.23. |  |